DDInter1269 DDInter604
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Medrysone
Medrysone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Drospirenone (Compound)
Nateglinide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Medrysone (Compound) and Medrysone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)